

## HR 8641

Orphan Drug COVID–19 Mitigation Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Aug 2, 2022

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (Aug 2, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/8641>

### Sponsor

**Name:** Rep. Gottheimer, Josh [D-NJ-5]

**Party:** Democratic • **State:** NJ • **Chamber:** House

### Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bacon, Don [R-NE-2]	R · NE		Aug 2, 2022
Rep. Dean, Madeleine [D-PA-4]	D · PA		Aug 2, 2022
Rep. Schrader, Kurt [D-OR-5]	D · OR		Oct 21, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Aug 2, 2022

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

*No related bills are listed.*

### Summary (as of Aug 2, 2022)

#### Orphan Drug COVID-19 Mitigation Act of 2022

This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.

### Actions Timeline

- **Aug 2, 2022:** Introduced in House
- **Aug 2, 2022:** Referred to the House Committee on Energy and Commerce.